Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Period	PE Ratio
2020-12-31	-4.43
2021-12-31	-6.25
2022-12-31	-5.67
2023-12-31	-4.64
2024-12-31	-5.43

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DYN	$18.31	+0.83%	0.75M
3
4
5

Dyne Therapeutics Inc. (DYN) PE Ratio

PE Ratio Data

Get Dyne Therapeutics Inc. Data in Excel

More DYN Financial Data